Literature DB >> 26557827

14th St. Gallen International Breast Cancer Conference 2015: Evidence, Controversies, Consensus - Primary Therapy of Early Breast Cancer: Opinions Expressed by German Experts.

Christian Jackisch1, Nadia Harbeck2, Jens Huober3, Gunter von Minckwitz4, Bernd Gerber5, Hans-Heinrich Kreipe6, Cornelia Liedtke7, Norbert Marschner8, Volker Möbus9, Heike Scheithauer10, Andreas Schneeweiss11, Christoph Thomssen12, Sibylle Loibl13, Matthias W Beckmann14, Jens-Uwe Blohmer15, Serban-Dan Costa16, Thomas Decker17, Ingo Diel18, Peter A Fasching19, Tanja Fehm20, Wolfgang Janni21, Hans-Joachim Lück22, Nicolai Maass23, Anton Scharl24, Michael Untch25.   

Abstract

The key topics of this year's 14th St. Gallen Consensus Conference on the diagnosis and therapy of primary breast cancer were again questions about breast surgery and axillary surgery, radio-oncology and systemic therapy options in consideration of tumor biology, and the clinical application of multigene assays. This year, the consensus conference took place in Vienna. From a German perspective, it makes sense to substantiate the results of the vote of the international panel representing 19 countries in light of the updated national therapy recommendations of the AGO (Arbeitsgemeinschaft Gynäkologische Onkologie). Therefore, 14 German breast cancer experts, 3 of whom are members of the International St. Gallen Panel, have commented on the voting results of the St. Gallen Consensus Conference 2015 in relation to clinical routine in Germany.

Entities:  

Keywords:  Endocrine therapy; Local therapy; Multigene assay; Sentinel node biopsy; St. Gallen Consensus 2015; Systemic therapy; Targeted substances

Year:  2015        PMID： 26557827      PMCID： PMC4569213          DOI： 10.1159/000433590

Source DB:  PubMed          Journal:  Breast Care (Basel)        ISSN： 1661-3791            Impact factor:   2.860


  18 in total

1.  Tailoring therapies--improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015.

Authors:  A S Coates; E P Winer; A Goldhirsch; R D Gelber; M Gnant; M Piccart-Gebhart; B Thürlimann; H-J Senn
Journal:  Ann Oncol       Date:  2015-05-04       Impact factor: 32.976

2.  Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8·1 years median follow-up.

Authors:  Meredith M Regan; Patrick Neven; Anita Giobbie-Hurder; Aron Goldhirsch; Bent Ejlertsen; Louis Mauriac; John F Forbes; Ian Smith; István Láng; Andrew Wardley; Manuela Rabaglio; Karen N Price; Richard D Gelber; Alan S Coates; Beat Thürlimann
Journal:  Lancet Oncol       Date:  2011-10-20       Impact factor: 41.316

3.  Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer.

Authors:  Sara M Tolaney; William T Barry; Chau T Dang; Denise A Yardley; Beverly Moy; P Kelly Marcom; Kathy S Albain; Hope S Rugo; Matthew Ellis; Iuliana Shapira; Antonio C Wolff; Lisa A Carey; Beth A Overmoyer; Ann H Partridge; Hao Guo; Clifford A Hudis; Ian E Krop; Harold J Burstein; Eric P Winer
Journal:  N Engl J Med       Date:  2015-01-08       Impact factor: 91.245

4.  Patient selection for accelerated partial-breast irradiation (APBI) after breast-conserving surgery: recommendations of the Groupe Européen de Curiethérapie-European Society for Therapeutic Radiology and Oncology (GEC-ESTRO) breast cancer working group based on clinical evidence (2009).

Authors:  Csaba Polgár; Erik Van Limbergen; Richard Pötter; György Kovács; Alfredo Polo; Jaroslaw Lyczek; Guido Hildebrandt; Peter Niehoff; Jose Luis Guinot; Ferran Guedea; Bengt Johansson; Oliver J Ott; Tibor Major; Vratislav Strnad
Journal:  Radiother Oncol       Date:  2010-02-22       Impact factor: 6.280

5.  Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.

Authors:  Gunter von Minckwitz; Andreas Schneeweiss; Sibylle Loibl; Christoph Salat; Carsten Denkert; Mahdi Rezai; Jens U Blohmer; Christian Jackisch; Stefan Paepke; Bernd Gerber; Dirk M Zahm; Sherko Kümmel; Holger Eidtmann; Peter Klare; Jens Huober; Serban Costa; Hans Tesch; Claus Hanusch; Jörn Hilfrich; Fariba Khandan; Peter A Fasching; Bruno V Sinn; Knut Engels; Keyur Mehta; Valentina Nekljudova; Michael Untch
Journal:  Lancet Oncol       Date:  2014-04-30       Impact factor: 41.316

6.  Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.

Authors:  Judy C Boughey; Vera J Suman; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Bret Taback; A Marilyn Leitch; Henry M Kuerer; Monet Bowling; Teresa S Flippo-Morton; David R Byrd; David W Ollila; Thomas B Julian; Sarah A McLaughlin; Linda McCall; W Fraser Symmans; Huong T Le-Petross; Bruce G Haffty; Thomas A Buchholz; Heidi Nelson; Kelly K Hunt
Journal:  JAMA       Date:  2013-10-09       Impact factor: 56.272

7.  Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression.

Authors:  Masashi Ando; Hideko Yamauchi; Kenjiro Aogi; Satoru Shimizu; Hiroji Iwata; Norikazu Masuda; Naohito Yamamoto; Kenichi Inoue; Shinji Ohono; Katsumasa Kuroi; Tetsutaro Hamano; Tamie Sukigara; Yasuhiro Fujiwara
Journal:  Breast Cancer Res Treat       Date:  2014-04-12       Impact factor: 4.872

8.  Identification and Resection of Clipped Node Decreases the False-negative Rate of Sentinel Lymph Node Surgery in Patients Presenting With Node-positive Breast Cancer (T0-T4, N1-N2) Who Receive Neoadjuvant Chemotherapy: Results From ACOSOG Z1071 (Alliance).

Authors:  Judy C Boughey; Karla V Ballman; Huong T Le-Petross; Linda M McCall; Elizabeth A Mittendorf; Gretchen M Ahrendt; Lee G Wilke; Bret Taback; Eric C Feliberti; Kelly K Hunt
Journal:  Ann Surg       Date:  2016-04       Impact factor: 12.969

9.  Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO).

Authors:  Benjamin D Smith; Douglas W Arthur; Thomas A Buchholz; Bruce G Haffty; Carol A Hahn; Patricia H Hardenbergh; Thomas B Julian; Lawrence B Marks; Dorin A Todor; Frank A Vicini; Timothy J Whelan; Julia White; Jennifer Y Wo; Jay R Harris
Journal:  Int J Radiat Oncol Biol Phys       Date:  2009-07-15       Impact factor: 7.038

10.  Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial.

Authors:  Jack Cuzick; Ivana Sestak; Michael Baum; Aman Buzdar; Anthony Howell; Mitch Dowsett; John F Forbes
Journal:  Lancet Oncol       Date:  2010-11-17       Impact factor: 41.316
View more
  14 in total

1.  What is better/reliable, mitosis counting or Ki67/MIB1 staining?

Authors:  Mark Kriegsmann; Arne Warth
Journal:  Transl Lung Cancer Res       Date:  2016-10

2.  Role of DCE-MR in predicting breast cancer subtypes.

Authors:  Marco Macchini; Martina Ponziani; Andrea Prochowski Iamurri; Mirco Pistelli; Mariagrazia De Lisa; Rossana Berardi; Gian Marco Giuseppetti
Journal:  Radiol Med       Date:  2018-06-05       Impact factor: 3.469

Review 3.  Tumor-Infiltrating Lymphocytes: A Promising Biomarker in Breast Cancer.

Authors:  Barbara Ingold Heppner; Sibylle Loibl; Carsten Denkert
Journal:  Breast Care (Basel)       Date:  2016-04-26       Impact factor: 2.860

4.  Reproductive outcomes following treatment for a gynecological cancer diagnosis: a systematic review.

Authors:  Brigitte Gerstl; Elizabeth Sullivan; Marcus Vallejo; Jana Koch; Maximilian Johnson; Handan Wand; Kate Webber; Angela Ives; Antoinette Anazodo
Journal:  J Cancer Surviv       Date:  2019-04-17       Impact factor: 4.442

Review 5.  The role of epigenetic modifications in drug resistance and treatment of breast cancer.

Authors:  Mohsen Karami Fath; Ali Azargoonjahromi; Arash Kiani; Fateme Jalalifar; Parisa Osati; Mahsa Akbari Oryani; Fateh Shakeri; Farhad Nasirzadeh; Behman Khalesi; Mohsen Nabi-Afjadi; Hamidreza Zalpoor; Maysam Mard-Soltani; Zahra Payandeh
Journal:  Cell Mol Biol Lett       Date:  2022-06-28       Impact factor: 8.702

6.  An analysis of Ki-67 expression in stage 1 invasive ductal breast carcinoma using apparent diffusion coefficient histograms.

Authors:  Maolin Xu; Qi Tang; Manxiu Li; Yulin Liu; Fang Li
Journal:  Quant Imaging Med Surg       Date:  2021-04

7.  Serum concentrations of active tamoxifen metabolites predict long-term survival in adjuvantly treated breast cancer patients.

Authors:  Thomas Helland; Nina Henne; Ersilia Bifulco; Bjørn Naume; Elin Borgen; Vessela N Kristensen; Jan T Kvaløy; Timothy L Lash; Grethe I G Alnæs; Ron H van Schaik; Emiel A M Janssen; Steinar Hustad; Ernst A Lien; Gunnar Mellgren; Håvard Søiland
Journal:  Breast Cancer Res       Date:  2017-11-28       Impact factor: 6.466

8.  Assessment of Ovarian Function in Phase 3 (Neo)adjuvant Breast Cancer Clinical Trials: A Systematic Evaluation.

Authors:  Wanyuan Cui; Prudence A Francis; Sherene Loi; Martha Hickey; Catharyn Stern; Lumine Na; Ann H Partridge; Sibylle Loibl; Richard A Anderson; Karla J Hutt; Louise A Keogh; Kelly-Anne Phillips
Journal:  J Natl Cancer Inst       Date:  2021-05-28       Impact factor: 11.816

9.  Value of Ki-67 expression in triple-negative breast cancer before and after neoadjuvant chemotherapy with weekly paclitaxel plus carboplatin.

Authors:  Ruo-Xi Wang; Sheng Chen; Xi Jin; Zhi-Ming Shao
Journal:  Sci Rep       Date:  2016-07-18       Impact factor: 4.379

10.  Risk stratification in luminal-type breast cancer: Comparison of Ki-67 with EndoPredict test results.

Authors:  Aurelia Noske; Sophie-Isabelle Anders; Johannes Ettl; Alexander Hapfelmeier; Katja Steiger; Katja Specht; Wilko Weichert; Marion Kiechle; Evelyn Klein
Journal:  Breast       Date:  2019-11-12       Impact factor: 4.380
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.